GB Sciences (GBLX) 10-K 30 Jun 22 2022 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2021
Document Information [Line Items]
Entity Central Index Key	0001165320
Entity Registrant Name	GB SCIENCES INC
Amendment Flag	false
Current Fiscal Year End Date	--03-31
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Document Type	10-K
Document Annual Report	true
Document Period End Date	Mar. 31, 2022
Document Transition Report	false
Entity File Number	000-55462
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	59-3733133
Entity Address, Address Line One	3550 W. Teco Avenue
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89118
City Area Code	866
Local Phone Number	721-0297
Title of 12(g) Security	Common Stock $.0001 Par Value
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Entity Shell Company	false
Entity Public Float			$ 11,300,000
Entity Common Stock, Shares Outstanding		329,204,224
Auditor Name	Assurance Dimensions, Inc.
Auditor Location	Margate, FL
Auditor Firm ID	5036

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Cash and cash equivalents	$ 233,893	$ 793,040
Prepaid expenses and other current assets	93,933	256,251
Current assets from discontinued operations	0	2,494,564
TOTAL CURRENT ASSETS	327,826	3,543,855
Property and equipment, net	0	25,022
Intangible assets, net of accumulated amortization of $104,201 and $43,096 at March 31, 2022 and 2021, respectively	2,222,074	1,706,762
Long term assets from discontinued operations	0	5,530,415
TOTAL ASSETS	2,549,900	10,806,054
CURRENT LIABILITIES:
Accounts payable	1,657,008	1,412,459
Accrued interest	384,769	493,741
Accrued liabilities	9,627	957,946
Notes and convertible notes payable, net of unamortized discount of $1,765 and $296,504 at March 31, 2022 and 2021, respectively	987,565	3,594,804
Indebtedness to related parties	0	84,913
Income tax payable	896,495	761,509
Current liabilities from discontinued operations	0	1,293,076
TOTAL CURRENT LIABILITIES	3,935,464	8,598,448
Convertible notes payable, net of unamortized discount of $99,489 and $154,590 at March 31, 2022 and 2021, respectively	397,308	292,410
Long term liabilities from discontinued operations	0	3,389,124
TOTAL LIABILITIES	4,332,772	12,279,982
Commitments and contingencies (Note 11)
STOCKHOLDERS' EQUITY/(DEFICIT):
Common Stock, $0.0001 par value, 600,000,000 shares authorized, 325,037,557 and 315,340,411 outstanding at March 31, 2022 and 2021, respectively	32,504	31,534
Additional paid-in capital	102,764,746	102,380,770
Accumulated deficit	(104,580,122)	(103,886,232)
TOTAL STOCKHOLDERS' EQUITY/(DEFICIT)	(1,782,872)	(1,473,928)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 2,549,900	$ 10,806,054

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Intangible assets, accumulated amortization	$ 104,201	$ 43,096
Unamortized discount, current	1,765	296,504
Unamortized discount, noncurrent	$ 99,489	$ 154,590
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	600,000,000	600,000,000
Common stock, shares issued (in shares)	325,037,557	315,340,411
Common stock, shares outstanding (in shares)	325,037,557	315,340,411

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Sales revenue	$ 0	$ 0
Cost of goods sold	0	0
Gross profit (loss)	0	0
General and administrative expenses	1,868,734	2,001,617
LOSS FROM OPERATIONS	(1,868,734)	(2,001,617)
OTHER INCOME (EXPENSE)
Gain on extinguishment	22,405	467,872
Gain on settlement of accounts payable	0	422,414
Gain on deconsolidation	5,206,208	0
Interest expense	(474,768)	(1,285,460)
Loss on modification of line of credit	0	(650,000)
Loss on impairment of note receivable	(3,025,000)	0
Debt default penalty	0	(286,059)
Loss on disposal	(15,639)	0
Other income	9,000	0
Total other income/(expense)	1,722,206	(1,331,233)
LOSS BEFORE INCOME TAXES	(146,528)	(3,332,850)
Income tax expense (Note 8)	0	0
LOSS FROM CONTINUING OPERATIONS	(146,528)	(3,332,850)
Net loss from discontinued operations (Note 4)	(384,345)	(392,177)
NET LOSS	(530,873)	(3,725,027)
Net loss attributable to common stockholders of GB Sciences, Inc. - basic and diluted
Continuing operations, basic	146,528	3,332,850
Discontinued operations, basic	384,345	392,177
Net loss	$ (530,873)	$ (3,725,027)
Net loss per common share – basic and diluted
Continuing operations (in dollars per share)	$ 0	$ (0.01)
Discontinued operations (in dollars per share)	0	0
Net loss (in dollars per share)	$ 0	$ (0.01)
Weighted average common shares outstanding - basic and diluted (in shares)	317,621,942	285,190,729

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity/(Deficit) - USD ($)	Compensation Warrant [Member] Common Stock [Member]	Compensation Warrant [Member] Additional Paid-in Capital [Member]	Compensation Warrant [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Mar. 31, 2020				275,541,602
Balance at Mar. 31, 2020				$ 27,554	$ 97,271,157	$ (97,387,205)	$ (88,494)
Issuance of stock for debt conversion (in shares)				4,000,000
Issuance of stock for debt conversion				$ 400	159,600		160,000
Exercise of warrants for stock (in shares)				35,798,809
Exercise of warrants for stock				$ 3,580	964,443		968,023
Share based compensation expense					436,349		436,349
Beneficial conversion feature on notes payable					543,886		543,886
Compensation warrants					231,335		231,335
Induced Dividend from Warrant Exercises					2,774,000	(2,774,000)
Net loss						(3,725,027)	(3,725,027)
Exercise of Warrants for Stock, Shares (in shares)				35,798,809
Exercise of warrants for stock				$ 3,580	964,443		968,023
Issuance of shares upon exercise of compensation warrants				$ 3,580	964,443		968,023
Stock options issued as compensation for drafting and filing patents							168,000
Balance (in shares) at Mar. 31, 2021				315,340,411
Balance at Mar. 31, 2021				$ 31,534	102,380,770	(103,886,232)	(1,473,928)
Exercise of warrants for stock (in shares)	7,601,813			2,095,333
Exercise of warrants for stock	$ 760	$ 75,308	$ 76,068	$ 210	56,184		56,394
Share based compensation expense					60,667		60,667
Induced Dividend from Warrant Exercises					163,017	(163,017)
Net loss						(530,873)	(530,873)
Exercise of Warrants for Stock, Shares (in shares)	7,601,813			2,095,333
Exercise of warrants for stock	$ 760	75,308	76,068	$ 210	56,184		56,394
Issuance of shares upon exercise of compensation warrants	$ 760	$ 75,308	$ 76,068	$ 210	56,184		56,394
Stock options issued as compensation for drafting and filing patents					28,800		28,800
Balance (in shares) at Mar. 31, 2022				325,037,557
Balance at Mar. 31, 2022				$ 32,504	$ 102,764,746	$ (104,580,122)	$ (1,782,872)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
OPERATING ACTIVITIES:
Net loss	$ (530,873)	$ (3,725,027)
Loss from discontinued operations	(384,345)	(392,177)
Net loss from continuing operations	(146,528)	(3,332,850)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	70,488	47,353
Stock-based compensation	60,667	436,349
Compensation warrants	0	231,335
Amortization of debt discount and beneficial conversion feature	356,340	776,122
Debt default penalty	0	286,059
Loss on modification of line of credit	0	650,000
Gain on extinguishment	(22,405)	(467,872)
Gain on settlement of accounts payable	0	(422,414)
Loss on disposal of assets	15,639	0
Loss on impairment of note receivable	3,025,000	0
Gain on deconsolidation	(5,206,208)	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	162,318	(237,475)
Accounts payable	821,253	(248,115)
Accrued expenses	(948,319)	166,828
Accrued interest	118,286	549,703
Indebtedness to related parties	(84,913)	(501,599)
Net cash used in operating activities of continuing operations	(1,778,382)	(2,066,576)
Net cash used in operating activities of discontinued operations	(87,772)	(118,644)
Net cash used in operating activities	(1,866,154)	(2,185,220)
INVESTING ACTIVITIES:
Proceeds from sale of Nevada Subsidiaries	1,648,772	0
Proceeds of note receivable	0	5,051,923
Acquisition of intangible assets	(200,000)	(292,675)
Net cash provided by investing activities of continuing operations	1,448,772	4,759,248
Net cash provided by/(used in) investing activities of discontinued operations	1,567	(103,729)
Net cash provided by investing activities	1,450,339	4,655,519
FINANCING ACTIVITIES:
Proceeds from warrant exercises	138,728	1,075,396
Proceeds from convertible notes payable	50,000	725,000
Proceeds from line of credit	0	375,000
Principal payment on notes payable	(575,000)	(3,156,014)
Principal payment on related party note	0	(151,923)
Brokerage fees from warrant exercises and stock issuances	(6,266)	(107,373)
Fees for issuance of convertible notes	0	(74,750)
Net cash used in financing activities of continuing operations	(392,538)	(1,314,664)
Net cash used in financing activities of discontinued operations	(103,387)	(161,768)
Net cash used in financing activities	(495,925)	(1,476,432)
NET CHANGE IN CASH AND CASH EQUIVALENTS	(911,740)	993,867
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	1,145,633	151,766
CASH AND CASH EQUIVALENTS AT END OF YEAR	233,893	1,145,633
Less: cash and cash equivalents classified as discontinued operations	0	(352,593)
CASH AND CASH EQUIVALENTS AT END OF YEAR FROM CONTINUING OPERATIONS	233,893	793,040
Cash paid for interest	0	241,014
Cash paid for income tax	0	0
Noncash investing and financing transactions:
Note receivable from sale of Nevada Subsidiaries	3,025,000	0
Extinguishment of debt and accrued interest owed to purchasers of Nevada Subsidiaries and purchasers' affiliates	2,612,854	0
Extinguishment of accrued management fees payable to purchaser of Nevada Subsidiaries	850,000	0
Accrued liabilities forgiven in connection with Wellcana Note settlement	0	172,500
Depreciation capitalized in inventory (discontinued operations)	349,015	532,785
Accrued interest capitalized in convertible note principal	0	223,094
Patent acquisition costs capitalized in intangible assets	347,617	319,939
Stock options issued for preparing capitalized patent applications	28,800	168,000
Stock issued upon conversion of notes payable	0	160,000
Inducement dividend from warrant exercises	163,017	2,774,000
Convertible Notes Payable [Member]
Noncash investing and financing transactions:
Beneficial conversion feature on notes payable	$ 0	$ 543,886

Note 1 - Background and Nature

Note 1 - Background and Nature of Operations	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	Note 1 Business GB Sciences, Inc. (“the Company”, “GB Sciences”, “we”, “us”, or “our”) is a phytomedical research and biopharmaceutical drug development company engaged in creating patented formulations of plant-inspired, complex therapeutic mixtures for the prescription drug market that target a variety of medical conditions. The Company is engaged in the research and development of plant-based medicines and plans to produce plant-inspired, complex therapeutic mixtures based on its portfolio of intellectual property. The Company is engaged in the research and development of plant-based medicines, primarily cannabinoid-inspired medicines, with virtual operations in North America and Europe. GBSGB’s assets include a portfolio of intellectual property containing both proprietary cannabinoid-containing formulations and our AI-enabled drug discovery platform, as well as critical research contracts and key supplier arrangements. GBSGB’s intellectual property covers a range of medical conditions and several programs are in the pre-clinical animal stage of development including Parkinson’s disease, neuropathic pain, and cardiovascular therapeutic programs. GBSGB runs a lean drug development program and takes effort to minimize expenses, including personnel, overhead, and fixed capital expenses through strategic partnerships with Universities and Contract Research Organizations (“CROs”). GBSGB’s intellectual property portfolio includes five nine one 35 We were incorporated in the State of Delaware on April 4, 2001, March 28, 2008, On April 4, 2014, December 12, 2016, Effective April 8, 2018, August 15, 2019, 400,000,000 Recent Developments Intellectual Property Portfolio On October 14th, 2020, In Silico Meta-Pharmacopeia Assembly from Non-Western Medical Systems Using Advanced Data Analytic Techniques to Identify and Design Phytotherapeutic Strategies”. GBSGB’s proprietary data analytics tool uses in silico convergence analysis to deconvolve modes of action and predict desirable components of plant-based formulations established in traditional medical practice based on computational consensus analysis across cultures and medical systems. On September 23rd, no January 31, 2018 December 8, 2020, 10,857,107. On April 7th, 2020, May 19, 2020, 10,653,640. On May 12th, 2020, July 14, 2020, 10,709,670. Divestiture of Nevada Cannabis Operations On March 24, 2020, On August 10, 2020, 483 October 23, 2017 ( 5 The closing of the Teco and Nopah sales was contingent upon the successful transfer of the Nevada cultivation and production licenses. On December 14, 2021, December 31, 2021. no As consideration for the membership interests, the Company received cash payments of $1,648,772 (including $400,000 in advance payments received during the nine December 31, 2021), 13

Note 2 - Going Concern

Note 2 - Going Concern	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	Note 2 The Company’s consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has sustained net losses since inception, which have caused an accumulated deficit of $104,580,122 at March 31, 2022 March 31, 2022 March 31, 2021 March 31, 2022 March 31, 2021 one Management has been able, thus far, to finance the losses through a public offering, private placements of debt and equity, and obtaining operating funds from stockholders. The Company is continuing to seek sources of financing. There are no In view of these conditions, the Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing or capital sources, to meet its financing requirements, and ultimately to achieve profitable operations. Management believes that its current and future plans provide an opportunity to continue as a going concern. The accompanying consolidated financial statements do not may

Note 3 - Basis of Presentation

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 3 Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, collectibility of notes receivable, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, income taxes payable were reclassified from current liabilities from discontinued operations to income taxes payable from discontinued operations, to reflect that this liability, while related to discontinued operations, remains an obligation of GB Sciences, Inc. and was not December 31, 2021 13 no Discontinued Operations See Note 4 Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three March 31, 2022 2021 Indefinite and Definite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also included the acquisition cost of a cannabis production license with an indefinite life as of March 31, 2021 We amortize our finite-lived intangible assets, which consist of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. At March 31, 2022 January 2038 May 2039. March 31, 2022 2021 March 31, 2022 There were 18 United States patent applications that are pending as of March 31, 2022 March 31, 2022 March 31, 2022 Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and had lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms which were primarily components of discontinued operations. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not Long-Lived Assets Property and equipment comprised a significant portion of our total assets from discontinued operations as of March 31, 2021. may March 31. may not Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, “Application of Issue No. 98 5 first 718 Compensation – Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2022 2021 Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operated in the State-licensed cannabis industry until the December 31, 2021 13 280E “280E” 280E, no not may not 280E. Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the year. The Company had 118,594,624 and 164,049,941 potentially dilutive common shares at March 31, 2022 2021 not Recent Accounting Pronouncements Standards Recently Adopted In May 2021, No. 2021 04, 2021 04 April 1, 2022. April 1, 2022 not Standards Not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 4 - Discontinued Operation

Note 4 - Discontinued Operations	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	Note 4 Discontinued Operations Discontinued operations comprise those activities that were disposed of during the period, or which were classified as held for sale at the end of the period and represent a separate major line of business or geographical area that can be clearly distinguished for operational and financial reporting purposes. The Company has included its subsidiaries GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC in discontinued operations due to the sale of the Company's Nevada Subsidiaries (Note 13 The assets and liabilities associated with discontinued operations included in our consolidated balance sheets as of March 31, 2022 2021 March 31, 2022 March 31, 2021 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 233,893 $ - $ 233,893 $ 793,040 $ 352,593 $ 1,145,633 Accounts receivable, net - - - - 400,175 400,175 Inventory, net - - - - 1,689,304 1,689,304 Prepaid and other current assets 93,933 - 93,933 256,251 52,492 308,743 TOTAL CURRENT ASSETS 327,826 - 327,826 1,049,291 2,494,564 3,543,855 Property and equipment, net - - - 25,022 4,876,247 4,901,269 Intangible assets, net 2,222,074 - 2,222,074 1,706,762 571,264 2,278,026 Deposits and other noncurrent assets - - - - 82,904 82,904 TOTAL ASSETS $ 2,549,900 $ - $ 2,549,900 $ 2,781,075 $ 8,024,979 $ 10,806,054 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,657,008 $ - $ 1,657,008 $ 1,412,459 $ 509,477 $ 1,921,936 Accrued interest 384,769 - 384,769 493,741 49,211 542,952 Accrued liabilities 9,627 - 9,627 957,946 105,421 1,063,367 Notes and convertible notes payable, net 987,565 - 987,565 3,594,804 485,000 4,079,804 Indebtedness to related parties - - - 84,913 - 84,913 Income tax payable 896,495 - 896,495 761,509 - 761,509 Finance lease obligations, current - - - - 143,967 143,967 TOTAL CURRENT LIABILITIES 3,935,464 - 3,935,464 7,305,372 1,293,076 8,598,448 Convertible notes payable, net 397,308 - 397,308 292,410 - 292,410 Finance lease obligations, long term - - - - 3,389,124 3,389,124 TOTAL LIABILITIES $ 4,332,772 $ - $ 4,332,772 $ 7,597,782 $ 4,682,200 $ 12,279,982 The revenues and expenses associated with discontinued operations included in our consolidated statements of operations for the years ended March 31, 2022 2021 For the Year Ended March 31, For the Year Ended March 31, 2022 2021 Continuing Discontinued - Nevada Total Continuing Discontinued - Nevada Total Sales revenue $ - $ 3,369,812 $ 3,369,812 $ - $ 4,110,456 $ 4,110,456 Cost of goods sold - (3,072,622 ) (3,072,622 ) - (3,506,722 ) (3,506,722 ) Gross profit (loss) - 297,190 297,190 - 603,734 603,734 General and administrative expenses 1,868,734 264,515 2,133,249 2,001,617 276,986 2,278,603 LOSS FROM OPERATIONS (1,868,734 ) 32,675 (1,836,059 ) (2,001,617 ) 326,748 (1,674,869 ) OTHER INCOME/(EXPENSE) Gain on extinguishment 22,405 - 22,405 467,872 - 467,872 Gain on settlement of accounts payable - - - 422,414 54,958 477,372 Gain on deconsolidation 5,206,208 - 5,206,208 - - - Interest expense (474,768 ) (302,923 ) (777,691 ) (1,285,460 ) (486,481 ) (1,771,941 ) Loss on modification of line of credit - - - (650,000 ) - (650,000 ) Loss on impairment of note receivable (3,025,000 ) - (3,025,000 ) - - - Debt default penalty - - - (286,059 ) - (286,059 ) Loss on disposal (15,639 ) - (15,639 ) - - - Other income 9,000 20,889 29,889 - (118,875 ) (118,875 ) TOTAL OTHER INCOME/(EXPENSE) 1,722,206 (282,034 ) 1,440,172 (1,331,233 ) (550,398 ) (1,881,631 ) NET LOSS BEFORE INCOME TAXES (146,528 ) (249,359 ) (395,887 ) (3,332,850 ) (223,650 ) (3,556,500 ) Income tax expense - (134,986 ) (134,986 ) - (168,527 ) (168,527 ) NET LOSS $ (146,528 ) $ (384,345 ) $ (530,873 ) $ (3,332,850 ) $ (392,177 ) $ (3,725,027 ) Discontinued Operations - Accounts Receivable Accounts receivable are carried at their estimated collectible amounts. Trade accounts receivable are periodically evaluated for collectability based on aging and subsequent collections. There were no accounts receivable at March 31, 2022 13 March 31, 2021. Discontinued Operations - Inventory We value inventory at the lower of the actual cost of our inventory, as determined using the first first Raw materials consist of supplies, materials, and consumables used in the cultivation and extraction processes. Work-in-progress consisted of live plants and cannabis in the drying, curing, and trimming processes. Finished goods includes completed cannabis flower, trim, and extracts in bulk and packaged forms. There is no remaining inventory on the Company's consolidated balance sheet as of March 31, 2022, 13 March 31, 2021. March 31, 2022 March 31, 2021 Inventory (discontinued operations) Raw materials $ - $ 86,076 Work in progress - 743,844 Finished goods - 866,195 Subtotal - 1,696,115 Allowance to reduce inventory to NRV - (6,811 ) Total inventory (discontinued operations) $ - $ 1,689,304 Discontinued Operations - Deposits and Noncurrent Assets Deposits and noncurrent assets from discontinued operations were $82,904 at March 31, 2021. March 31, 2022, March 31, 2021. Discontinued Operations - Leases The Company evaluates all finance and operating leases, and they are measured on the balance sheet with a lease liability and right-of-use asset (“ROU”) at inception. ROU assets represent the Company’s right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of 12 not The Company's only remaining lease commitment was a finance lease for the Nevada Subsidiaries, which is classified as discontinued operations in the Company's consolidated balance sheet at March 31, 2021. December 31, 2025 December 31, 2030. Finance leases are included in property and equipment (long term assets from discontinued operations), finance lease obligations, short term (current liabilities from discontinued operations), and finance lease obligations, long term (long term liabilities from discontinued operations), on the balance sheet as of March 31, 2021. The right-of-use asset and lease liability were deconsolidated at December 31, 2021 March 31, 2022 2021 March 31, Lease costs (discontinued operations) Classification on the Statements of Operations 2022 2021 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ 116,024 $ 154,699 Finance leases - interest on lease liabilities Loss from discontinued operations 301,796 414,993 Operating leases Loss from discontinued operations - 3,243 Total lease cost, discontinued operations $ 417,820 $ 572,935 Discontinued Operations - 8% Line of Credit dated November 27, 2019 In connection with the Binding Letter of Intent dated November 27, 2019 13 not December 29, 2020, no November 30, 2020. December 31, 2021 March 31, 2021

Note 5 - Notes Payable and Line

Note 5 - Notes Payable and Line of Credit	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5 0% October 23, 2017 On October 23, 2017, one three January 1, 2018. On August 10, 2020, December 31, 2021 December 14, 2021 13 On March 4, 2022, We evaluated the modification under the guidance in ASC 470 50 10% The Company made a $75,000 payment pursuant to the terms of the modification on March 4, 2022. March 31, 2022 8% July 24, 2020 On July 24, 2020, "July 24 may 8% February 28, 2019. July 24 3 July 24 On December 29, 2020, three $325,000 July 24 July 24 one No November 30, 2020. not July 24 March 31, 2021. December 31, 2021, $325,000 March 31, 2021, December 31, 2021, no 13 Summary of Notes Payable As of March 31, 2022 As of March 31, 2022 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended), current portion (Note 5) $ 54,330 $ - $ 54,330 6% Convertible promissory notes payable (Note 6) 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 (1,765 ) 48,235 Total short-term notes and convertible notes payable $ 989,330 $ (1,765 ) $ 987,565 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (26,254 ) $ 170,746 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (73,235 ) 176,765 0% Note Payable dated October 23, 2017 (as amended), long term portion (Note 5) 49,797 - 49,797 Total long term convertible notes payable classified as continuing operations $ 496,797 $ (99,489 ) $ 397,308 As of March 31, 2021 As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410

Note 6 - Convertible Notes

Note 6 - Convertible Notes	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Convertible Debt [Text Block]	Note 6 March 2017 July 2017 In March 2017, third three March 2017 May 2017, three three In July 2017, third three July 2017 December 2017, three three All notes from the March July 2017 March 31, 2022 $197,000 three September 30, 2023. 10% March 31, 2022 $197,000 March 31, 2022 Three convertible notes totaling $1,060,000 held by the same investor are past maturity and are currently in default. On January 20, 2022, one three not March 31, 2022 8% Convertible Promissory Note dated February 28, 2019 On February 28, 2019, August 28, 2020, On December 29, 2020, November 30, 2020. December 31, 2021. Upon close of the Teco sale on December 31, 2021, 13 8% April 23, 2019 On April 23, 2019, April 22, 2020. During the year ended March 31, 2020, October 30, 2019, November 18, 2019, On April 22, 2020, 10% March 31, 2021 On May 20, 2020, July 14, 2020, On November 20, 2020, December 8, 2020. December 8, 2020, December 9, 2020, not December 16, 2020, December 18, 2020, no December 2020 $625,000 6% On December 18, 2020, 19 three January 31, 2021 July 1, 2022, December 2023. March 31, 2022, At March 31, 2022 March 31, 2022

Note 7 - Property and Equipment

Note 7 - Property and Equipment	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 7 Property and equipment is recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset or, in the case of leasehold improvements amortized over the lesser of the useful life of the asset or the underlying lease term. We recorded depreciation expense of $25,775 and $34,654 on a consolidated basis for the years ended year ended March 31, 2022 2021 March 31, 2022 2021 March 31, 2022, no 13

Note 8 - Income Taxes

Note 8 - Income Taxes	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 8 The Company files income tax returns in the U.S. federal jurisdiction. The Company operates in the state of Nevada, which does not The Company’s effective tax rate was 1.8% and-3.6% for the years ended March 31, 2022 2021 Income tax expense was $134,986 for the year ended March 31, 2022 March 31, 2018 March 31, 2021 March 31, 2022 March 31, 2021 March 31, 2018 March 31, 2021 March 31, 2022 2021 Because the Company operates in the State-licensed cannabis industry, it is subject to the limitations of Internal Revenue Code Section 280E “280E” 280E, no may not 280E. At March 31, 2022 2021 2025 2039. March 31, 2019 no may 50% The provision for income taxes included in discontinued operations is different than would result from applying the U.S. statutory rate to profit before taxes for the reasons set forth in the following reconciliation: 2022 2021 Tax expense/(benefit) computed at U.S. statutory rates $ 691,042 $ (697,040 ) Increases (decreases) in taxes resulting from: IRC Section 280E 132,063 173,045 Other permanent items 5,526 14,407 Change in valuation allowance 579,861 26,720 Adjustments to valuation of deferred tax assets (1,408,492 ) 603,319 Tax return true-up 58,277 - Total provision for income taxes 58,277 120,451 Penalties and interest on prior year tax liabilities 76,709 48,076 Total income tax expense $ 134,986 $ 168,527 The tax effects of the primary temporary differences giving rise to the Company’s deferred tax assets and liabilities are as follows for the year ended March 31, 2022 2021 2022 2021 Deferred tax assets: Stock based compensation $ 3,144,084 $ 3,131,344 Net operating loss carryforward 10,816,588 10,460,788 Impairment of long-lived assets - 975,461 Depreciation and Amortization expense (1,369 ) (458,938 ) Other temporary items (209,714 ) 220,795 Total deferred tax assets 13,749,589 14,329,450 Less valuation allowance (13,749,589 ) (14,329,450 ) Net deferred tax asset $ - $ - Deferred tax assets are evaluated by considering historical levels of income, estimates of future taxable income and the impact of tax planning strategies. The Company continues to evaluate its deferred tax asset valuation allowance on a quarterly basis. The Company concluded that, as of March 31, 2022 not not The Company believes that the tax positions taken in its tax returns would be sustained upon examination by taxing authorities. The Company files income tax returns in the U.S. federal jurisdiction and other required state jurisdictions. The Company's periodic tax returns filed in 2019

Note 9 - Capital Transactions

Note 9 - Capital Transactions	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	Note 9 Year Ended March 31, 2022 On April 1, 2020, $.05 July 18, 2021, September 30, 2021 one three March 31, 2022, On March 1, 2022, During the year ended March 31, 2022, one ten six During the year ended March 31, 2022, March 31, 2022. Year Ended March 31, 2021 On April 1, 2020, $0.03 $.05 March 31, 2021, During the year ended March 31, 2021, one ten During the year ended March 31, 2021, three three 6 On November 16, 2020, November 16, 2025, June 1, 2023. On December 7, 2020, ten On December 15, 2020, ten one third one third one one third two March 31, 2021. March 31, 2021. On December 15, 2020, On January 2, 2021, January 2, 2024. December 11, 2020 October 1, 2023, During the quarter ended March 31, 2021, 6 On February 8, 2021, December 2019 three Warrants Outstanding Presented below is a summary of the Company’s warrant activity, exclusive of warrants held by employees (Note 10 March 31, 2022 2021 Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2020 84,538,161 Warrants issued 43,493,809 $0.10 Warrants exercised (35,798,809) 0.03000.03535 Warrants expired/cancelled (6,390,125) 0.6000.9090 Outstanding at March 31, 2021 85,843,036 Warrants issued 2,095,333 $0.10 Warrants exercised (9,697,146) $0.01- $0.03 Warrants expired/cancelled (3,116,550) $0.60 Outstanding at March 31, 2022 75,124,673

Note 10 - Employee Benefit Plan

Note 10 - Employee Benefit Plan	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	Note 10 Share-Based Employee Compensation On February 6, 2008, 2007 “2007 2007 may 2014 June 30, 2015, 8 April 6, 2018, 2014 2018 October 25, 2018, 8 2018 On September 17, 2021, 2021 "2021 8 2021 2021 March 31, 2022 Compensation Expense For the years ended March 31, 2022 2021 March 31, 2022 Fair Value The closing price of the Company's stock on the date of grant is used as the fair value for issuances of restricted stock. The fair value of stock options granted is estimated as of the grant date using the Black-Scholes option pricing model. The following range of assumptions in the Black-Scholes option pricing model was used to determine fair value: Year Ended March 31, 2022 March 31, 2021 Weighted-average volatility 131 % 127 % Expected term (in years) 10 % 10 Risk-free interest rate 1.42 % 0.93 % Expected volatilities used for award valuation are based on historical volatility of the Company's common stock. The risk-free interest rate for periods equal to the expected term of an award is based on Federal Reserve yields for U.S. Treasury securities. Stock Options A summary of employee option activity, including warrants issued to employees, as of March 31, 2022 2021 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Granted 6,750,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Granted - Exercised - Forfeited - Outstanding at March 31, 2022 17,733,334 $ 0.11 5.80 $ - Fully vested and expected to vest at March 31, 2022 17,733,334 $ 0.11 Exercisable at March 31, 2022 15,566,668 $ 0.12 The table below sets forth nonemployee option activity for the years ended March 31, 2022 2021 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2020 2,383,000 $ 0.27 6.75 $ - Granted 3,500,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ - Granted 600,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2022 6,483,000 $ 0.13 7.31 $ - Fully vested and expected to vest at March 31, 2022 6,483,000 $ 0.13 Exercisable at March 31, 2022 6,483,000 $ 0.13 Restricted stock awards No restricted stock awards were granted during the years ended March 31, 2022 2021

Note 11 - Commitments and Conti

Note 11 - Commitments and Contingencies	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 11 On April 11, 2022, May 2020. may On April 22, 2020, May 20, 2020, July 14, 2020, December 16, 2020 6 On April 22, 2020, September 17, 2020, From time to time, the Company may not

Note 12 - Related Party Transac

Note 12 - Related Party Transactions	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 12 During the year ended March 31, 2022 March 31, 2022 On September 1, 2019, 9 January 2, 2021, On November 16, 2020, March 31, 2021. In connection with the sale of membership interest in GB Sciences Louisiana, LLC, the Company issued a note payable in the amount of $151,923 to John Davis, the Company's former General Counsel and President of GB Sciences Louisiana, LLC, for unpaid compensation and bonuses. The note matured upon receipt of the first August 4, 2020.

Note 13 - Sale of Membership In

Note 13 - Sale of Membership Interests in Nevada Subsidiaries	12 Months Ended
	Mar. 31, 2022
Nevada Subsidiaries [Member]
Notes to Financial Statements
Noncontrolling Interest Disclosure [Text Block]	Note 13 On March 24, 2020, On August 10, 2020, 483 October 23, 2017 5 The closing of the Teco and Nopah sales was contingent upon the successful transfer of the Nevada cultivation and production licenses. On December 14, 2021, December 31, 2021. As consideration for the membership interests, the Company received cash payments of $1,648,772 (including $400,000 in advance payments received during the nine December 31, 2021), 5 6 As the result of sale of the Nevada Subsidiaries, the Company recorded a gain on deconsolidation of $5,206,208 on December 31, 2021, December 31, 2021 Cash payments received, including advancements of $400,000 $ 1,648,772 8% Note Receivable due December 31, 2024 3,025,000 Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates 2,612,854 Extinguishment of accrued management fees due to purchaser 850,000 Total consideration 8,136,626 Carrying amount of assets 7,130,159 Carrying amount of liabilities (4,199,741 ) Net assets deconsolidated 2,930,418 GAIN ON DECONSOLIDATION $ 5,206,208 As the result of sale, the income, assets, and cash flows of GB Sciences Nevada, LLC, GB Sciences Las Vegas, LLC, and GB Sciences Nopah, LLC have been reclassified as discontinued operations for all periods presented in the Company's consolidated financial statements prior to the sale. Note Receivable from Sale of Teco Subsidiaries The $3,025,000 note receivable from the sale of the Teco Subsidiaries is payable as quarterly, interest only payments of $60,500 for the first March 31, 2023, December 31, 2024. The note contains a provision that allows payments of principal and interest due prior to the maturity date to be postponed to the next quarterly payment date if cash flow from the operations of the facility is insufficient to cover the amount of the payment. Several days prior to the first April 1, 2022, April 1, 2022 July 1, 2022

Note 14 - Concentrations

Note 14 - Concentrations	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 14 We held no cash deposits in excess of FDIC limits as of March 31, 2022 March 31, 2021 March 31, 2022 December 31, 2021 13

Note 15 - Subsequent Events

Note 15 - Subsequent Events	12 Months Ended
	Mar. 31, 2022
Notes to Financial Statements
Subsequent Events [Text Block]	Note 15 May 9, 2022 five one five

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Mar. 31, 2022
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation We prepare our consolidated financial statements in accordance with generally accepted accounting principles (GAAP) for the United States of America. Our consolidated financial statements include all operating divisions and majority-owned subsidiaries, reported as a single operating segment, for which we maintain controlling interests. The subsidiaries of the Company are: Continuing Operations: GBS Global Biopharma, Inc. ECRX, Inc. The PhAROS Institute, LLC GB Sciences Texas, LLC Discontinued Operations: GB Sciences Nevada, LLC GB Sciences Las Vegas, LLC GB Sciences Nopah, LLC Intercompany accounts and transactions have been eliminated in consolidation. The ownership interest of non-controlling participants in subsidiaries that are not
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to allowances for doubtful accounts, collectibility of notes receivable, inventory valuation and standard cost allocations, valuation of initial right-of-use assets and corresponding lease liabilities, valuation of beneficial conversion features in convertible debt, valuation of the assets and liabilities of discontinued operations, stock-based compensation expense, purchased intangible asset valuations, deferred income tax asset valuation allowances, uncertain tax positions, litigation, other loss contingencies, and impairment of long lived assets. These estimates and assumptions are based on current facts, historical experience and various other factors that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of costs and expenses that are not may
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications Certain reclassifications have been made to the comparative period amounts in order to conform to the current period presentation. In particular, income taxes payable were reclassified from current liabilities from discontinued operations to income taxes payable from discontinued operations, to reflect that this liability, while related to discontinued operations, remains an obligation of GB Sciences, Inc. and was not December 31, 2021 13 no
Discontinued Operations, Policy [Policy Text Block]	Discontinued Operations See Note 4
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three - Level 1 - Level 2 - Level 3 The carrying value of cash, accounts receivable, accounts payable and accrued expenses are estimated by management to approximate fair value, primarily due to the short-term nature of the instruments.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three March 31, 2022 2021
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Indefinite and Definite-Lived Intangible Assets Our indefinite-lived intangible assets primarily represent the value of our patents pending and includes the costs paid to draft and file patent applications. Upon issuance of the patents, the indefinite-lived intangible assets will have finite lives. Intangible assets also included the acquisition cost of a cannabis production license with an indefinite life as of March 31, 2021 We amortize our finite-lived intangible assets, which consist of granted patents, over their estimated useful lives using the straight-line method, and we periodically evaluate the remaining useful lives of our finite-lived intangible assets to determine whether events or circumstances warrant a revision to the remaining period of amortization. We review all of our intangible assets for impairment indicators throughout the year. Impairment testing for indefinite-lived intangible assets is performed at least annually and we perform testing for definite-lived intangible assets whenever impairment indicators are present. If we determine that the fair value is less than the carrying value of these assets during testing, we record impairment losses equal to the difference between the carrying value of the asset and the fair market value of the asset. At March 31, 2022 January 2038 May 2039. March 31, 2022 2021 March 31, 2022 There were 18 United States patent applications that are pending as of March 31, 2022 March 31, 2022 March 31, 2022
Lessee, Leases [Policy Text Block]	Operating Lease Right-of-Use Asset and Liability The Company determines if an arrangement is a lease at inception and had lease agreements for office facilities, equipment, and other space and assets with non-cancelable lease terms which were primarily components of discontinued operations. Certain real estate and property leases, and various other operating leases are measured on the balance sheet with a lease liability and right-of-use asset ("ROU"). ROU assets represent the Company's right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make scheduled lease payments. ROU assets and liabilities are recognized on the lease commencement date based on the present value of lease payments over the lease term. The present value of lease payments is calculated using the incremental borrowing rate at lease commencement, which takes into consideration recent debt issuances as well as other applicable market data available. Lease payments include fixed payments, variable payments based on an index or rate, reasonably certain purchase options, termination penalties, and others as required by the New Lease Standard. Lease payments do not Lease terms include options to extend when it is reasonably certain that the option will be exercised. Leases with a term of twelve not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets: 3 8 not
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets Property and equipment comprised a significant portion of our total assets from discontinued operations as of March 31, 2021. may March 31. may not
Debt, Policy [Policy Text Block]	Beneficial Conversion Feature of Convertible Notes Payable The Company accounts for convertible notes payable in accordance with the guidelines established by the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 470 20, Debt with Conversion and Other Options 00 27, “Application of Issue No. 98 5 first 718 Compensation – Stock Compensation The value of the proceeds received from a convertible note is then allocated between the conversion features and warrants on a relative fair value basis. The allocated fair value is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition The FASB issued Accounting Standards Codification (“ASC”) 606 two April 1, 2018 The Company’s only material revenue source is part of discontinued operations and derives from sales of cannabis and cannabis products, distinct physical goods. Under ASC 606, may may one 606 not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs Research and development costs are expensed as incurred. During the years ended March 31, 2022 2021
Share-Based Payment Arrangement [Policy Text Block]	Equity-Based Compensation The Company accounts for equity instruments issued to employees and non-employees in accordance with the provisions of ASC 718 718 no may may may
Income Tax, Policy [Policy Text Block]	Income Taxes The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in financial statements or tax returns. Deferred tax items are reflected at the enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Due to the uncertainty regarding the success of future operations, management has valued the deferred tax asset allowance at 100% Because the Company operated in the State-licensed cannabis industry until the December 31, 2021 13 280E “280E” 280E, no not may not 280E.
Earnings Per Share, Policy [Policy Text Block]	Loss per Share The Company’s basic loss per share has been calculated using the weighted average number of common shares outstanding during the year. The Company had 118,594,624 and 164,049,941 potentially dilutive common shares at March 31, 2022 2021 not
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements Standards Recently Adopted In May 2021, No. 2021 04, 2021 04 April 1, 2022. April 1, 2022 not Standards Not On June 16, 2016, No. 2016 13, April 1, 2023. 2016 13 In June 2020, No. 2020 06, may April 1, 2024. 2020 06 All other newly issued accounting pronouncements have been deemed either immaterial or not

Note 4 - Discontinued Operati_2

Note 4 - Discontinued Operations (Tables)	12 Months Ended
	Mar. 31, 2022
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	March 31, 2022 March 31, 2021 Continuing Discontinued Nevada Subsidiaries Total Continuing Discontinued Nevada Subsidiaries Total ASSETS CURRENT ASSETS Cash $ 233,893 $ - $ 233,893 $ 793,040 $ 352,593 $ 1,145,633 Accounts receivable, net - - - - 400,175 400,175 Inventory, net - - - - 1,689,304 1,689,304 Prepaid and other current assets 93,933 - 93,933 256,251 52,492 308,743 TOTAL CURRENT ASSETS 327,826 - 327,826 1,049,291 2,494,564 3,543,855 Property and equipment, net - - - 25,022 4,876,247 4,901,269 Intangible assets, net 2,222,074 - 2,222,074 1,706,762 571,264 2,278,026 Deposits and other noncurrent assets - - - - 82,904 82,904 TOTAL ASSETS $ 2,549,900 $ - $ 2,549,900 $ 2,781,075 $ 8,024,979 $ 10,806,054 LIABILITIES CURRENT LIABILITIES Accounts payable $ 1,657,008 $ - $ 1,657,008 $ 1,412,459 $ 509,477 $ 1,921,936 Accrued interest 384,769 - 384,769 493,741 49,211 542,952 Accrued liabilities 9,627 - 9,627 957,946 105,421 1,063,367 Notes and convertible notes payable, net 987,565 - 987,565 3,594,804 485,000 4,079,804 Indebtedness to related parties - - - 84,913 - 84,913 Income tax payable 896,495 - 896,495 761,509 - 761,509 Finance lease obligations, current - - - - 143,967 143,967 TOTAL CURRENT LIABILITIES 3,935,464 - 3,935,464 7,305,372 1,293,076 8,598,448 Convertible notes payable, net 397,308 - 397,308 292,410 - 292,410 Finance lease obligations, long term - - - - 3,389,124 3,389,124 TOTAL LIABILITIES $ 4,332,772 $ - $ 4,332,772 $ 7,597,782 $ 4,682,200 $ 12,279,982 For the Year Ended March 31, For the Year Ended March 31, 2022 2021 Continuing Discontinued - Nevada Total Continuing Discontinued - Nevada Total Sales revenue $ - $ 3,369,812 $ 3,369,812 $ - $ 4,110,456 $ 4,110,456 Cost of goods sold - (3,072,622 ) (3,072,622 ) - (3,506,722 ) (3,506,722 ) Gross profit (loss) - 297,190 297,190 - 603,734 603,734 General and administrative expenses 1,868,734 264,515 2,133,249 2,001,617 276,986 2,278,603 LOSS FROM OPERATIONS (1,868,734 ) 32,675 (1,836,059 ) (2,001,617 ) 326,748 (1,674,869 ) OTHER INCOME/(EXPENSE) Gain on extinguishment 22,405 - 22,405 467,872 - 467,872 Gain on settlement of accounts payable - - - 422,414 54,958 477,372 Gain on deconsolidation 5,206,208 - 5,206,208 - - - Interest expense (474,768 ) (302,923 ) (777,691 ) (1,285,460 ) (486,481 ) (1,771,941 ) Loss on modification of line of credit - - - (650,000 ) - (650,000 ) Loss on impairment of note receivable (3,025,000 ) - (3,025,000 ) - - - Debt default penalty - - - (286,059 ) - (286,059 ) Loss on disposal (15,639 ) - (15,639 ) - - - Other income 9,000 20,889 29,889 - (118,875 ) (118,875 ) TOTAL OTHER INCOME/(EXPENSE) 1,722,206 (282,034 ) 1,440,172 (1,331,233 ) (550,398 ) (1,881,631 ) NET LOSS BEFORE INCOME TAXES (146,528 ) (249,359 ) (395,887 ) (3,332,850 ) (223,650 ) (3,556,500 ) Income tax expense - (134,986 ) (134,986 ) - (168,527 ) (168,527 ) NET LOSS $ (146,528 ) $ (384,345 ) $ (530,873 ) $ (3,332,850 ) $ (392,177 ) $ (3,725,027 )
Lease, Cost [Table Text Block]	March 31, Lease costs (discontinued operations) Classification on the Statements of Operations 2022 2021 Discontinued operations: Finance leases - amortization of ROU assets Loss from discontinued operations $ 116,024 $ 154,699 Finance leases - interest on lease liabilities Loss from discontinued operations 301,796 414,993 Operating leases Loss from discontinued operations - 3,243 Total lease cost, discontinued operations $ 417,820 $ 572,935
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Notes Tables
Schedule of Inventory, Current [Table Text Block]	March 31, 2022 March 31, 2021 Inventory (discontinued operations) Raw materials $ - $ 86,076 Work in progress - 743,844 Finished goods - 866,195 Subtotal - 1,696,115 Allowance to reduce inventory to NRV - (6,811 ) Total inventory (discontinued operations) $ - $ 1,689,304

Note 5 - Notes Payable and Li_2

Note 5 - Notes Payable and Line of Credit (Tables)	12 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Debt [Table Text Block]	As of March 31, 2022 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (as amended), current portion (Note 5) $ 54,330 $ - $ 54,330 6% Convertible promissory notes payable (Note 6) 560,000 - 560,000 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 - 325,000 6% Convertible note payable due July 1, 2022 (Note 6) 50,000 (1,765 ) 48,235 Total short-term notes and convertible notes payable $ 989,330 $ (1,765 ) $ 987,565 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (26,254 ) $ 170,746 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (73,235 ) 176,765 0% Note Payable dated October 23, 2017 (as amended), long term portion (Note 5) 49,797 - 49,797 Total long term convertible notes payable classified as continuing operations $ 496,797 $ (99,489 ) $ 397,308 As of March 31, 2021 Face Value Discount Carrying Value 0% Note Payable dated October 23, 2017 (Note 5) $ 369,445 $ - $ 369,445 8% Line of Credit dated November 27, 2019 (Note 5) 485,000 - 485,000 8% Line of Credit dated July 24, 2020 (Note 5) 1,025,000 - 1,025,000 6% Convertible promissory notes payable (Note 6) 1,060,000 - 1,060,000 8% Convertible Secured Promissory Note dated February 28, 2019, as amended (Note 6) 1,111,863 - 1,111,863 6% Convertible notes payable due January 18, 2022 (Note 6) 325,000 (296,504 ) 28,496 Total short-term notes and convertible notes payable 4,376,308 (296,504 ) 4,079,804 Less: Notes payable classified as discontinued operations (485,000 ) - (485,000 ) Total short term notes and convertible notes payable classified as continuing operations $ 3,891,308 $ (296,504 ) $ 3,594,804 6% Convertible promissory notes payable due September 30, 2023 (Note 6) $ 197,000 $ (40,561 ) $ 156,439 6% Convertible note payable due December 31, 2023 (Note 6) 250,000 (114,029 ) 135,971 Total long term convertible notes payable classified as continuing operations $ 447,000 $ (154,590 ) $ 292,410

Note 8 - Income Taxes (Tables)

Note 8 - Income Taxes (Tables)	12 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2022 2021 Tax expense/(benefit) computed at U.S. statutory rates $ 691,042 $ (697,040 ) Increases (decreases) in taxes resulting from: IRC Section 280E 132,063 173,045 Other permanent items 5,526 14,407 Change in valuation allowance 579,861 26,720 Adjustments to valuation of deferred tax assets (1,408,492 ) 603,319 Tax return true-up 58,277 - Total provision for income taxes 58,277 120,451 Penalties and interest on prior year tax liabilities 76,709 48,076 Total income tax expense $ 134,986 $ 168,527
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2022 2021 Deferred tax assets: Stock based compensation $ 3,144,084 $ 3,131,344 Net operating loss carryforward 10,816,588 10,460,788 Impairment of long-lived assets - 975,461 Depreciation and Amortization expense (1,369 ) (458,938 ) Other temporary items (209,714 ) 220,795 Total deferred tax assets 13,749,589 14,329,450 Less valuation allowance (13,749,589 ) (14,329,450 ) Net deferred tax asset $ - $ -

Note 9 - Capital Transactions (

Note 9 - Capital Transactions (Tables)	12 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Warrants Outstanding Number of Shares Exercise Price Outstanding at March 31, 2020 84,538,161 Warrants issued 43,493,809 $0.10 Warrants exercised (35,798,809) 0.03000.03535 Warrants expired/cancelled (6,390,125) 0.6000.9090 Outstanding at March 31, 2021 85,843,036 Warrants issued 2,095,333 $0.10 Warrants exercised (9,697,146) $0.01- $0.03 Warrants expired/cancelled (3,116,550) $0.60 Outstanding at March 31, 2022 75,124,673

Note 10 - Employee Benefit Pl_2

Note 10 - Employee Benefit Plan (Tables)	12 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Year Ended March 31, 2022 March 31, 2021 Weighted-average volatility 131 % 127 % Expected term (in years) 10 % 10 Risk-free interest rate 1.42 % 0.93 %
Schedule of Stock Options Roll Forward [Table Text Block]	Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Employee options and warrants Options Price $ Life (years) Value ($) Outstanding at March 31, 2020 10,983,334 $ 0.28 6.02 $ - Granted 6,750,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 17,733,334 $ 0.11 6.80 $ 172,000 Granted - Exercised - Forfeited - Outstanding at March 31, 2022 17,733,334 $ 0.11 5.80 $ - Fully vested and expected to vest at March 31, 2022 17,733,334 $ 0.11 Exercisable at March 31, 2022 15,566,668 $ 0.12 Weighted Weighted Average Average Remaining Aggregate Exercise Contractual Intrinsic Nonemployee options Options Price $ Life (years) Value ($) Outstanding at March 31, 2020 2,383,000 $ 0.27 6.75 $ - Granted 3,500,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2021 5,883,000 $ 0.14 8.11 $ - Granted 600,000 $ 0.05 Exercised - Forfeited - Outstanding at March 31, 2022 6,483,000 $ 0.13 7.31 $ - Fully vested and expected to vest at March 31, 2022 6,483,000 $ 0.13 Exercisable at March 31, 2022 6,483,000 $ 0.13

Note 13 - Sale of Membership _2

Note 13 - Sale of Membership Interests in Nevada Subsidiaries (Tables)	12 Months Ended
	Mar. 31, 2022
Notes Tables
Schedule of Deconsolidation [Table Text Block]	December 31, 2021 Cash payments received, including advancements of $400,000 $ 1,648,772 8% Note Receivable due December 31, 2024 3,025,000 Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates 2,612,854 Extinguishment of accrued management fees due to purchaser 850,000 Total consideration 8,136,626 Carrying amount of assets 7,130,159 Carrying amount of liabilities (4,199,741 ) Net assets deconsolidated 2,930,418 GAIN ON DECONSOLIDATION $ 5,206,208

Note 1 - Background and Natur_2

Note 1 - Background and Nature of Operations (Details Textual) - USD ($)							9 Months Ended		12 Months Ended
	Dec. 31, 2021	Dec. 14, 2021	Aug. 10, 2020	Mar. 24, 2020	Nov. 27, 2019	Oct. 23, 2017	Dec. 31, 2021	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021	Aug. 15, 2019	Apr. 08, 2018	Mar. 31, 2018
Common Stock, Shares Authorized (in shares)									600,000,000	600,000,000	600,000,000	400,000,000	250,000,000
Notes Reduction									$ 2,612,854	$ 0
Proceeds from Divestiture of Interest in Consolidated Subsidiaries									1,648,772	$ 0
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage			0%			0%
Receivable with Imputed Interest, Effective Yield (Interest Rate)						20.30%
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership					100%
Sale of Interest, Percentage of Ownership			100%
Noncash or Part Noncash Divestiture, Amount of Consideration Received			$ 312,315
Nevada Subsidiaries [Member]
Sale of Stock, Percentage of Ownership				100%
Teco Subsidiaries [Member]
Sale of Stock, Consideration Received on Transaction				$ 8,000,000
Notes Receivable, Interest Rate				8%
GB Sciences Nopah, LLC [Member]
Notes Reduction			237,668
Extinguishment of Debt, Amount							$ 3,462,854	$ 3,462,854
Sale of Stock, Percentage of Ownership before Transaction	100%
Proceeds from Divestiture of Interest in Consolidated Subsidiaries								1,648,772	$ 1,648,772
Proceeds From Divestiture of Business, Advances Received	$ 400,000						400,000	400,000
Financing Receivable, after Allowance for Credit Loss, Total	3,025,000						$ 3,025,000	$ 3,025,000
Receivable with Imputed Interest, Effective Yield (Interest Rate)							8%	8%
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member]
Extinguishment of Debt, Amount	$ 74,647	$ 74,647	$ 74,647

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Retained Earnings (Accumulated Deficit), Total	$ (104,580,122)	$ (103,886,232)
Working Capital (Deficit)	(3,607,638)	(5,054,593)
Net Cash Provided by (Used in) Operating Activities, Total	(1,866,154)	(2,185,220)
Cash Provided by (Used in) Operating Activities, Discontinued Operations	(87,772)	(118,644)
Discontinued Operations [Member]
Working Capital (Deficit)		(1,201,488)
Cash Provided by (Used in) Operating Activities, Discontinued Operations	$ (87,772)	$ (118,644)

Note 3 - Basis of Presentatio_2

Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)	12 Months Ended
	Mar. 31, 2022 USD ($) shares	Mar. 31, 2021 USD ($) shares
Short-Term Investments, Total	$ 0	$ 0
Finite-Lived Intangible Assets, Net, Ending Balance	$ 2,222,074	1,706,762
Indefinite-Lived Intangible Assets, Pending, Number	18
Research and Development Expense, Total	$ 821,321	$ 352,274
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares	118,594,624	164,049,941
Minimum [Member]
Property, Plant and Equipment, Useful Life (Year)	3 years
Maximum [Member]
Property, Plant and Equipment, Useful Life (Year)	8 years
Licensed Patents [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance	$ 928,667
Trademarks [Member]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending Balance	$ 15,089
Patents [Member]
Finite-Lived Intangible Assets, Number	6
Amortization of Intangible Assets	$ 61,105	$ 34,555
Finite-Lived Intangible Assets, Net, Ending Balance		$ 1,278,318
Patents [Member] | GBS Global Biopharma, Inc [Member]
Finite-Lived Intangible Assets, Number	4
Licensed Patents [Member]
Finite-Lived Intangible Assets, Number	2

Note 4 - Discontinued Operati_3

Note 4 - Discontinued Operations (Details Textual) - USD ($)	12 Months Ended		28 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Dec. 31, 2021	Nov. 27, 2019
Inventory, Net, Total		$ 0
Proceeds from Lines of Credit, Total	$ 0	375,000
Line of Credit [Member]
Debt Instrument, Interest Rate, Stated Percentage					8%
Line of Credit Facility, Maximum Borrowing Capacity					$ 470,000
Proceeds from Lines of Credit, Total			$ 485,000
Line of Credit Facility, Maximum Borrowing Capacity, Increased			$ 15,000
Long-term Line of Credit, Total				$ 485,000
Interest Payable				$ 49,211
Maximum [Member]
Lessee, Finance Lease, Discount Rate	11.50%		11.50%
Discontinued Operations [Member]
Accounts Receivable, after Allowance for Credit Loss, Total	$ 0		$ 0
Inventory, Net, Total		1,689,304
Deposits Assets, Noncurrent	$ 0	$ 82,904	$ 0

Note 4 - Discontinued Operati_4

Note 4 - Discontinued Operations - Discontinued Operations (Details) - USD ($)		12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Cash		$ 233,893	$ 793,040
Inventory, net			0
Prepaid and other current assets		93,933	256,251
TOTAL CURRENT ASSETS		327,826	3,543,855
Property and equipment, net		0	25,022
Finite-Lived Intangible Assets, Net, Ending Balance		2,222,074	1,706,762
TOTAL ASSETS		2,549,900	10,806,054
Accounts payable		1,657,008	1,412,459
Accrued interest		384,769	493,741
Accrued liabilities		9,627	957,946
Indebtedness to related parties		0	84,913
Income tax payable		896,495	761,509
Convertible notes payable, net		397,308	292,410
TOTAL LIABILITIES		4,332,772	12,279,982
Sales revenue		0	0
Cost of goods sold		0	0
Gross profit (loss)		0	0
General and administrative expenses		1,868,734	2,001,617
Gain on extinguishment		22,405	467,872
Gain on settlement of accounts payable		0	422,414
Gain on deconsolidation	$ 5,206,208	5,206,208	0
Interest expense		(474,768)	(1,285,460)
Loss on modification of line of credit		0	(650,000)
Loss on impairment of note receivable		(3,025,000)	0
Debt default penalty		0	(286,059)
Loss on disposal		(15,639)	0
Other income		9,000	0
Total other income/(expense)		1,722,206	(1,331,233)
Income tax expense (Note 8)		0	0
NET LOSS		(384,345)	(392,177)
Continuing Operations [Member]
Cash		233,893	793,040
Prepaid and other current assets		93,933	256,251
TOTAL CURRENT ASSETS		327,826	1,049,291
Property and equipment, net			25,022
Finite-Lived Intangible Assets, Net, Ending Balance		2,222,074	1,706,762
TOTAL ASSETS		2,549,900	2,781,075
Accounts payable		1,657,008	1,412,459
Accrued interest		384,769	493,741
Accrued liabilities		9,627	957,946
Notes and convertible notes payable, net		987,565	3,594,804
Indebtedness to related parties			84,913
Income tax payable		896,495	761,509
Convertible notes payable, net		397,308	292,410
TOTAL LIABILITIES		4,332,772	7,597,782
Sales revenue		0	0
Cost of goods sold		0	0
Gross profit (loss)		0	0
General and administrative expenses		1,868,734	2,001,617
LOSS FROM OPERATIONS		(1,868,734)	(2,001,617)
Gain on extinguishment		22,405	467,872
Gain on settlement of accounts payable		0	422,414
Gain on deconsolidation		5,206,208	0
Interest expense		(474,768)	(1,285,460)
Loss on modification of line of credit		0	(650,000)
Loss on impairment of note receivable		(3,025,000)	0
Debt default penalty		0	(286,059)
Loss on disposal		(15,639)	0
Other income		9,000	0
Total other income/(expense)		1,722,206	(1,331,233)
NET LOSS BEFORE INCOME TAXES		(146,528)	(3,332,850)
Income tax expense (Note 8)		0	0
NET LOSS		(146,528)	(3,332,850)
Discontinued Operations [Member]
Cash		0	352,593
Accounts receivable, net			400,175
Inventory, net			1,689,304
Prepaid and other current assets		0	52,492
TOTAL CURRENT ASSETS			2,494,564
Property and equipment, net			4,876,247
Finite-Lived Intangible Assets, Net, Ending Balance			571,264
Deposits and other noncurrent assets		0	82,904
TOTAL ASSETS			8,024,979
Accounts payable			509,477
Accrued interest			49,211
Accrued liabilities			105,421
Notes and convertible notes payable, net			485,000
Finance lease obligations, current			143,967
Finance lease obligations, long term			3,389,124
TOTAL LIABILITIES			4,682,200
Sales revenue		3,369,812	4,110,456
Cost of goods sold		(3,072,622)	(3,506,722)
Gross profit (loss)		297,190	603,734
General and administrative expenses		264,515	276,986
LOSS FROM OPERATIONS		32,675	326,748
Gain on extinguishment		0	0
Gain on settlement of accounts payable		0	54,958
Gain on deconsolidation		0	0
Interest expense		(302,923)	(486,481)
Loss on modification of line of credit		0	0
Loss on impairment of note receivable		0	0
Debt default penalty		0	0
Loss on disposal		0	0
Other income		20,889	(118,875)
Total other income/(expense)		(282,034)	(550,398)
NET LOSS BEFORE INCOME TAXES		(249,359)	(223,650)
Income tax expense (Note 8)		(134,986)	(168,527)
NET LOSS		(384,345)	(392,177)
Segment, Continuing and Discontinued Operations [Member]
Cash		233,893	1,145,633
Accounts receivable, net			400,175
Inventory, net			1,689,304
Prepaid and other current assets		93,933	308,743
TOTAL CURRENT ASSETS		327,826	3,543,855
Property and equipment, net			4,901,269
Finite-Lived Intangible Assets, Net, Ending Balance		2,222,074	2,278,026
Deposits and other noncurrent assets			82,904
TOTAL ASSETS		2,549,900	10,806,054
Accounts payable		1,657,008	1,921,936
Accrued interest		384,769	542,952
Accrued liabilities		9,627	1,063,367
Notes and convertible notes payable, net		987,565	4,079,804
Indebtedness to related parties			84,913
Income tax payable		896,495	761,509
Finance lease obligations, current			143,967
Convertible notes payable, net		397,308	292,410
Finance lease obligations, long term			3,389,124
TOTAL LIABILITIES		4,332,772	12,279,982
Sales revenue		3,369,812	4,110,456
Cost of goods sold		(3,072,622)	(3,506,722)
Gross profit (loss)		297,190	603,734
General and administrative expenses		2,133,249	2,278,603
LOSS FROM OPERATIONS		(1,836,059)	(1,674,869)
Gain on extinguishment		22,405	467,872
Gain on settlement of accounts payable		0	477,372
Gain on deconsolidation		5,206,208	0
Interest expense		(777,691)	(1,771,941)
Loss on modification of line of credit		0	(650,000)
Loss on impairment of note receivable		(3,025,000)	0
Debt default penalty		0	(286,059)
Loss on disposal		(15,639)	0
Other income		29,889	(118,875)
Total other income/(expense)		1,440,172	(1,881,631)
NET LOSS BEFORE INCOME TAXES		(395,887)	(3,556,500)
Income tax expense (Note 8)		(134,986)	(168,527)
NET LOSS		$ (530,873)	$ (3,725,027)

Note 4 - Discontinued Operati_5

Note 4 - Discontinued Operations - Schedule of Inventory (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Total inventory (discontinued operations)		$ 0
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]
Raw materials	$ 0	86,076
Work in progress	0	743,844
Finished goods	0	866,195
Subtotal	0	1,696,115
Allowance to reduce inventory to NRV	0	(6,811)
Total inventory (discontinued operations)	$ 0	$ 1,689,304

Note 4 - Discontinued Operati_6

Note 4 - Discontinued Operations - Lease Costs Recorded in the Company's Financial Statements (Details) - Discontinued Operations [Member] - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Finance leases - amortization of ROU assets	$ 116,024	$ 154,699
Finance leases - interest on lease liabilities	301,796	414,993
Operating leases	0	3,243
Total lease cost, discontinued operations	$ 417,820	$ 572,935

Note 5 - Notes Payable and Li_3

Note 5 - Notes Payable and Line of Credit (Details Textual)							1 Months Ended	9 Months Ended		12 Months Ended
	Mar. 04, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 14, 2021 USD ($)	Dec. 29, 2020 USD ($)	Aug. 10, 2020 USD ($)	Oct. 23, 2017 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)	Jul. 24, 2020 USD ($)
Gain (Loss) on Extinguishment of Debt, Total										$ 22,405	$ 467,872
Gain (Loss) on Amendment to Line of Credit										0	(650,000)
GB Sciences Nopah, LLC [Member]
Receivable with Imputed Interest, Effective Yield (Interest Rate)								8%	8%
Extinguishment of Debt, Amount								$ 3,462,854	$ 3,462,854
Financing Receivable, after Allowance for Credit Loss, Total		$ 3,025,000						3,025,000	3,025,000
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member]
Extinguishment of Debt, Amount		74,647	$ 74,647		$ 74,647
Teco Subsidiaries [Member] | The July 24 Note [Member]
Financing Receivable, after Allowance for Credit Loss, Total		1,025,000		$ 3,025,000				1,025,000	1,025,000
Increase (Decrease) in Notes Receivable, Current				975,000
Notes Receivable, Maximum Allowed Prepayments On Note				325,000
Disposal Group, Including Discontinued Operation, Consideration				$ 4,000,000
Gain (Loss) on Amendment to Line of Credit											$ (650,000)
Notes Receivable, Additional Advances									50,000
Interest and Debt Expense, Total									12,510
The July 24 Note [Member] | Revolving Credit Facility [Member]
Debt Instrument, Interest Rate, Stated Percentage												8%
Line of Credit Facility, Maximum Borrowing Capacity												$ 500,000
The July 24 Note [Member] | Teco Subsidiaries [Member]
Financing Receivable, after Allowance for Credit Loss, Total												$ 4,000,000
Debt Instrument, Forgiveness, Ratio of Notes Receivable Amount Reduced to the Debt Balance Outstanding												3
Promissory Note [Member]
Debt Instrument, Face Amount							$ 496,797			496,797
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage					0%	0%
Debt Instrument, Face Amount						$ 700,000
Debt Instrument, Term (Year)						3 years
Debt Instrument, Present Value						$ 521,067
Receivable with Imputed Interest, Effective Yield (Interest Rate)						20.30%
Debt Instrument, Unamortized Discount, Total						$ 178,933
Notes Payable, Current, Total		$ 369,445						$ 369,445	$ 369,445
Notes Payable, Principal and Interest	$ 201,532
Notes Payable, Principal and Interest, After Modified Terms	179,127
Repayment of Notes Payable	75,000									75,000
Debt Instrument, Monthly Payment, Amount	$ 5,000
Debt Instrument, Interest Rate, Stated Percentage, After Term Modification	8%
Gain (Loss) on Extinguishment of Debt, Total							22,405
Notes Payable, Current and Noncurrent							104,127			104,127
Interest Payable							$ 616			$ 616
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member] | Membership Interest Purchase Agreement for Sale of Interest in GB Sciences Nopah, LLC [Member]
Debt Instrument, Principal Balance After Reduction Upon Close of Disposition					$ 190,272
Nevada Medical Marijuana Production License Agreement [Member]
Payments to Acquire License						$ 500,000
Nevada Medical Marijuana Production License Agreement [Member] | Production License [Member]
Ownership of License						100%
Nevada Medical Marijuana Production License Agreement [Member] | Cultivation License [Member]
Ownership of License						100%

Note 5 - Notes Payable and Li_4

Note 5 - Notes Payable and Line of Credit - Summary of Notes and Convertible Notes Payable (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021	Oct. 23, 2017
Discount, short-term notes payable	$ (99,489)	$ (154,590)
Discount, short-term notes payable	(1,765)	(296,504)
Promissory Note [Member]
Short-Term Notes Payable	496,797
Discount, short-term notes payable	(99,489)	(154,590)
Carrying value, long-term notes payable	397,308	292,410
Total short term notes and convertible notes payable classified as continuing operations		447,000
Face Value, long-term notes payable		447,000
The 0% Note Payable Dated October 23, 2017 [Member] | Note Payable [Member]
Short-Term Notes Payable	49,797
Carrying value, long-term notes payable	49,797
The 0% Note Payable Dated October 23, 2017 [Member] | Promissory Note [Member]
Short-Term Notes Payable			$ 700,000
The 6 % Note Payable Dated September 30, 2023 [Member] | Convertible Debt [Member]
Short-Term Notes Payable	197,000	197,000
Discount, short-term notes payable	(26,254)	(40,561)
Carrying value, long-term notes payable	170,746	156,439
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Convertible Debt [Member]
Short-Term Notes Payable	250,000
Discount, short-term notes payable	(73,235)
Carrying value, long-term notes payable	176,765
The 6 % Note Payable Dated December 31, 2023 [Member] | Convertible Debt [Member]
Short-Term Notes Payable		250,000
Discount, short-term notes payable		(114,029)
Carrying value, long-term notes payable		135,971
Note Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Short-Term Notes Payable	54,330
Carrying value, short-term notes payable	54,330
Convertible Notes Payable [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Short-Term Notes Payable		369,445
Carrying value, short-term notes payable		369,445
Discount, short-term notes payable		0
Convertible Notes Payable [Member] | The 6% Note Payable Due November 30, 2018 [Member]
Short-Term Notes Payable	560,000	1,060,000
Carrying value, short-term notes payable	560,000	1,060,000
Discount, short-term notes payable		0
Convertible Notes Payable [Member] | The 6% Notes Payable Due January 18, 2022 [Member]
Short-Term Notes Payable	325,000	325,000
Carrying value, short-term notes payable	325,000	28,496
Discount, short-term notes payable		(296,504)
Convertible Notes Payable [Member] | The 6% Notes Payable Due July 1, 2022 [Member]
Short-Term Notes Payable	50,000
Carrying value, short-term notes payable	48,235
Discount, short-term notes payable	(1,765)
Line of Credit [Member] | The 8% Line of Credit Dated November 27, 2019 [Member]
Short-Term Notes Payable		485,000
Carrying value, short-term notes payable		485,000
Discount, short-term notes payable		0
Line of Credit [Member] | The 8% Line of Credit Dated July 24, 2020 [Member]
Short-Term Notes Payable		1,025,000
Carrying value, short-term notes payable		1,025,000
Discount, short-term notes payable		0
Promissory Note [Member]
Short-Term Notes Payable	989,330	4,376,308
Carrying value, short-term notes payable	987,565	4,079,804
Discount, short-term notes payable	$ (1,765)
Discount, short-term notes payable		(296,504)
Less: Notes payable classified as discontinued operations, face value		(485,000)
Less: Notes payable classified as discontinued operations, discount		0
Less: Notes payable classified as discontinued operations, carrying value		(485,000)
Total short term notes and convertible notes payable classified as continuing operations		3,891,308
Total short term notes and convertible notes payable classified as continuing operations		(296,504)
Total short term notes and convertible notes payable classified as continuing operations		3,594,804
Face Value, long-term notes payable		3,891,308
Senior Secured Convertible Promissory Note [Member] | The Amended 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Short-Term Notes Payable		1,111,863
Carrying value, short-term notes payable		1,111,863
Discount, short-term notes payable		$ 0

Note 6 - Convertible Notes (Det

Note 6 - Convertible Notes (Details Textual)								1 Months Ended			3 Months Ended		6 Months Ended		9 Months Ended	12 Months Ended
	Dec. 16, 2020 USD ($)	Jul. 14, 2020 USD ($)	Apr. 22, 2020 USD ($)	Nov. 18, 2019 USD ($) $ / shares shares	Oct. 30, 2019 USD ($) $ / shares shares	Apr. 23, 2019 USD ($) $ / shares	Feb. 28, 2019 USD ($) $ / shares	Jan. 31, 2022 USD ($)	Jul. 31, 2017 USD ($) $ / shares	Mar. 31, 2017 USD ($) $ / shares	Mar. 31, 2021 USD ($) $ / shares shares	May 31, 2017 USD ($) $ / shares shares	Sep. 30, 2020 USD ($)	Dec. 31, 2017 USD ($) $ / shares shares	Dec. 18, 2020 USD ($) $ / shares	Mar. 31, 2022 USD ($) $ / shares shares	Mar. 31, 2021 USD ($) $ / shares shares	Mar. 31, 2020 USD ($)	Dec. 31, 2021 USD ($) Rate	Dec. 09, 2020 USD ($)	Nov. 20, 2020 USD ($)
Class of Warrant or Right, Issued During Period (in shares) | shares																2,095,333	43,493,809
Amortization of Debt Discount (Premium)																$ 356,340	$ 776,122
Debt Default Penalty																0	286,059
Proceeds from Convertible Debt																50,000	725,000
Convertible Notes Payable, Current											$ 3,594,804					987,565	3,594,804
Debt Instrument, Unamortized Discount, Current											296,504					1,765	296,504
Convertible Notes Payable, Noncurrent											292,410					397,308	292,410
Debt Instrument, Unamortized Discount, Noncurrent											154,590					99,489	154,590
Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Debt Instrument, Debt Default, Interest Rate Penalty		15%
Litigation Settlement, Amount Awarded to Other Party		$ 3,264,594
Litigation Settlement, Amount Final Settlement																				$ 3,006,015	$ 3,006,015
Litigation Settlement, One Time Required Payment																				25,000
Litigation Settlement, Weekly Required Payment																				$ 25,000
Litigation Settlement, Payment	$ 3,006,015
Discontinued Operations, Disposed of by Sale [Member] | Teco Sale [Member]
Notes and Accrued Interest Payable, Exchange Reduction, Percentage (Rate) | Rate																			110%
Disposal Group, Including Discontinued Operation, Consideration																			$ 4,000,000
Increase (Decrease) Liability Due from Exchange Reduction, Percentage (Rate) | Rate																			10%
Increase (Decrease) Liability Due from Exchange Reduction, Value																			$ 125,686
Convertible Debt [Member]
Debt Instrument, Extended Amount											197,000						197,000
Convertible Notes Payable, Total																560,000
Interest Expense, Debt, Total																286,119
Interest Payable																57,846
Debt Instrument, Debt Default, Amount																$ 1,060,000
Repayments of Convertible Debt								$ 500,000
Warrants Issued in March 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Number of Warrants										4,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares										$ 0.60		$ 0.60
Warrants and Rights Outstanding, Term (Year)										3 years		3 years
Class of Warrant or Right, Issued (in shares) | shares												8,000,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares												1
Warrants Issued In March 2017 and July 2017 Convertible Note Offerings [Member]
Debt Instrument, Convertible, Number of Warrants									4,000
Class of Warrant or Right, Issued During Period (in shares) | shares																788,000
Warrants Related to July 2017 Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares									$ 0.65					$ 0.60
Warrants and Rights Outstanding, Term (Year)														3 years
Class of Warrant or Right, Issued (in shares) | shares														28,804,000
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares														1
Warrants Issued in September 30, 2023, Convertible Note Offering [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares																$ 0.10
Warrants and Rights Outstanding, Term (Year)																3 years
Warrants and Rights Outstanding																$ 13,396
March And July 2017 Convertible Note Offering [Member] | Convertible Debt [Member]
Debt Instrument, Unamortized Discount, Total																46,886
Debt Instrument, Convertible, Beneficial Conversion Feature																33,490
Interest Expense, Debt, Total																26,127
Amortization of Debt Discount (Premium)																14,306
Interest Payable																56,152
Interest Payable, Accrued Prior to Extinguishments																38,438
The 6 % Convertible Note Payable Dated December 31, 2023 [Member]
Debt Instrument, Interest Rate, Stated Percentage															6%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares															$ 0.05
Interest Expense, Debt, Total																378,777
Amortization of Debt Discount (Premium)																342,033
Convertible Notes Payable, Current																373,235
Debt Instrument, Unamortized Discount, Current																1,765
Convertible Notes Payable, Noncurrent																176,765
Debt Instrument, Unamortized Discount, Noncurrent																73,235
The 6 % Convertible Note Payable Dated December 31, 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount															$ 625,000
The 6 % Convertible Note Payable Mature in December 2021 [Member] | Three Investors [Member]
Debt Instrument, Face Amount															375,000
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Three Investors [Member]
Debt Instrument, Face Amount															250,000
The 6 % Convertible Note Payable Mature in December 2023 [Member] | Convertible Debt [Member]
Debt Instrument, Face Amount																250,000
Debt Instrument, Unamortized Discount, Noncurrent																73,235
The 6 Percent Convertible Note Payable Issued With In Money Conversion Features [Member]
Debt Instrument, Face Amount															425,000
Debt Instrument, Unamortized Discount, Total															81,250	6,500
Debt Instrument, Convertible, Beneficial Conversion Feature															347,000
Proceeds from Convertible Debt															$ 543,750	50,000
Convertible Notes Payable [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature																$ 0	543,886
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note										$ 1,000
Debt Instrument, Interest Rate, Stated Percentage										6%
Debt Instrument, Face Amount												$ 2,000,000
Debt Instrument, Term (Year)												3 years
Debt Instrument, Unamortized Discount, Total												$ 1,933,693
Debt Instrument, Convertible, Beneficial Conversion Feature												904,690
Debt Instrument, Convertible, Discount, Fair Value of Warrants												$ 1,029,003
Convertible Notes Payable [Member] | March 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments										4,000		8,000,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares										$ 0.25
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Face Amount Per Note									$ 1,000
Debt Instrument, Face Amount														$ 7,201,000
Debt Instrument, Term (Year)									3 years					3 years
Debt Instrument, Unamortized Discount, Total														$ 7,092,796
Debt Instrument, Convertible, Beneficial Conversion Feature														3,142,605
Debt Instrument, Convertible, Discount, Fair Value of Warrants														$ 3,950,191
Convertible Notes Payable [Member] | July 2017 Convertible Note Offering [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments									4,000					28,804,000
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares									$ 0.25
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares																$ 0.10
Debt Instrument, Extended Amount																$ 197,000
Convertible Notes Payable, Total																1,257,000
Convertible Notes Payable [Member] | The 8% Convertible Promissory Note Dated April 23, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage						8%
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares				$ 0.0375	$ 0.06	$ 0.17
Debt Instrument, Face Amount						$ 2,765,000
Debt Instrument, Unamortized Discount, Total						265,000
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net, Total						440,000
Payments for Brokerage Fees						$ 175,000
Debt Conversion, Original Debt, Amount				$ 50,000	$ 75,000													$ 125,000
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares				1,333,333	1,250,000
Induced Conversion of Convertible Debt Expense					$ 64,706
Debt Instrument, Debt Default, Interest Rate Penalty			10%
Debt Instrument, Debt Default, Interest Expense			$ 9,559
Debt Instrument, Debt Default, Principal Expense			$ 276,500
Debt Instrument, Debt Default, Increase in Principal Amount, Percent			10%
Debt Default Penalty													$ 286,059
Promissory Note [Member]
Debt Instrument, Face Amount											4,376,308					989,330	4,376,308
Short-term Debt, Total											4,079,804					987,565	4,079,804
Debt Instrument, Unamortized Discount, Current											296,504						$ 296,504
Debt Instrument, Unamortized Discount, Noncurrent																$ 1,765
Promissory Note [Member] | July 2017 Convertible Note Offering [Member]
Debt Instrument, Interest Rate, Stated Percentage									6%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Instrument, Interest Rate, Stated Percentage							8%
Debt Instrument, Face Amount							$ 1,500,000
Interest Payable																			144,994
Short-term Debt, Total																			$ 1,111,863
Debt Conversion, Original Debt, Amount											$ 160,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | GB Sciences, Nevada, LLC [Member] | Collateral Pledged [Member]
Noncontrolling Interest, Ownership Percentage by Parent							100%
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Number of Equity Instruments							8,823,529
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ / shares							$ 0.17				$ 0.04						$ 0.04
Debt Conversion, Converted Instrument, Shares Issued (in shares) | shares											4,000,000

Note 7 - Property and Equipme_2

Note 7 - Property and Equipment (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Depreciation, Total	$ 25,775	$ 34,654
Depreciation, Capitalized to Inventory	349,015	532,785
Discontinued Operations [Member]
Depreciation, Total	$ 16,391	$ 21,855

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2018
Effective Income Tax Rate Reconciliation, Percent, Total	1.80%	(3.60%)
Income Tax Expense (Benefit), Continuing Operations, Discontinued Operations	$ 134,986	$ 168,527
Income Tax Reconciliation, Prior Year Tax Penalties		207,945	$ 53,955
Income Tax Reconciliation, Accrued Interest on Prior Year Tax Liabilities			22,754
Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount		178,727	$ 506,145
Taxes Payable, Current, Total	896,495	592,982
Operating Loss Carryforwards	51,507,562	$ 51,063,886
Operating Loss Carryforwards, Subject to Expiration	34,481,122
Operating Loss Carryforwards, Not Subject to Expiration	$ 17,026,440

Note 8 - Income Taxes - Reconci

Note 8 - Income Taxes - Reconciliation of Effective Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Tax expense/(benefit) computed at U.S. statutory rates	$ 691,042	$ (697,040)
IRC Section 280E	132,063	173,045
Other permanent items	5,526	14,407
Change in valuation allowance	579,861	26,720
Adjustments to valuation of deferred tax assets	(1,408,492)	603,319
Tax return true-up	58,277	0
Total provision for income taxes	58,277	120,451
Penalties and interest on prior year tax liabilities	76,709	48,076
Total income tax expense	$ 134,986	$ 168,527

Note 8 - Income Taxes - Deferre

Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Stock based compensation	$ 3,144,084	$ 3,131,344
Net operating loss carryforward	10,816,588	10,460,788
Impairment of long-lived assets	0	975,461
Depreciation and Amortization expense	(1,369)	(458,938)
Other temporary items	(209,714)	(220,795)
Other temporary items	209,714	220,795
Total deferred tax assets	13,749,589	14,329,450
Less valuation allowance	(13,749,589)	(14,329,450)
Net deferred tax asset	$ 0	$ 0

Note 9 - Capital Transactions_2

Note 9 - Capital Transactions (Details Textual) - USD ($)						3 Months Ended	11 Months Ended	12 Months Ended
	Mar. 01, 2022	Jan. 02, 2021	Dec. 15, 2020	Dec. 07, 2020	Nov. 16, 2020	Mar. 31, 2021	Mar. 03, 2022	Mar. 31, 2022	Mar. 31, 2021	Jul. 18, 2021	Feb. 08, 2021	Jan. 01, 2021	Mar. 31, 2020	Feb. 28, 2019
Proceeds from Warrant Exercises								$ 138,728	$ 1,075,396
Class of Warrant or Right, Issued During Period (in shares)								2,095,333	43,493,809
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)								$ 0.10	$ 0.10
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total								$ 17,333
Class of Warrant or Right, Outstanding (in shares)						85,843,036		75,124,673	85,843,036				84,538,161
Class of Warrant or Right, Expense								$ 60,667	$ 211,000
Common Stock [Member]
Exercise of Warrants for Stock, Shares (in shares)								2,095,333	35,798,809
Convertible Debt [Member]
Debt Instrument, Extended Amount						$ 197,000			$ 197,000
Convertible Notes Payable [Member] | March And July 2017 Convertible Note Offering [Member]
Debt Instrument, Extension Period (Year)									3 years
Debt Instrument, Extended Amount								$ 197,000
Debt Instrument, Convertible, Conversion Price (in dollars per share)								$ 0.10
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member]
Debt Conversion, Original Debt, Amount						$ 160,000
Senior Secured Convertible Promissory Note [Member] | The 8% Senior Secured Convertible Promissory Note Dated February 28, 2019 [Member] | Common Stock [Member]
Debt Instrument, Convertible, Conversion Price (in dollars per share)						$ 0.04			$ 0.04					$ 0.17
Debt Conversion, Converted Instrument, Shares Issued (in shares)						4,000,000
Scientist and Researcher [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)									3,500,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)									$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value									$ 168,000
Former Director [Member]
Share-based Payment Arrangement, Expense					$ 6,300
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)					$ 0.03
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)					450,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period Before Modification, Fair Value					$ 4,950
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period After Modification, Fair Value					$ 11,250
Employees and Directors [Member]
Share-based Payment Arrangement, Expense									62,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			3,250,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Fair Value									156,000
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount						$ 78,000			78,000
Current Employees [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 0.05
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)			6,050,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period Before Modification, Fair Value			$ 199,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period After Modification, Fair Value			250,650
Share-Based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense			$ 51,050				$ 60,667	$ 60,667	$ 436,349
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total								17,333
Share-Based Payment Arrangement, Option [Member] | Scientist and Researcher [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)									10 years
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)			10 years
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage			33.30%
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage			33.30%
Share-Based Payment Arrangement, Option [Member] | Employees and Directors [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage			33.30%
Share-Based Payment Arrangement, Nonemployee [Member]
Share-based Payment Arrangement, Expense								$ 28,800
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)								600,000	3,500,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)								$ 0.05	$ 0.05
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)						5,883,000		6,483,000	5,883,000				2,383,000
Minimum [Member]
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)									$ 0.030
Maximum [Member]
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)									$ 0.035
Warrants Issued to Investors in Private Placements [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)										$ 0.10
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)										1
Warrants and Rights Outstanding, Term (Year)										3 years
Class of Warrant or Right, Exercises in Period (in shares)	7,601,813							2,095,333	35,798,809
Class of Warrant or Right, Exercised During Period, Exercise Price (in dollars per share)	$ 0.01							$ 0.03
Proceeds from Warrant Exercises	$ 76,068							$ 56,394	$ 968,023
Brokerage Fees for Issuance of Common Stock and Warrants								6,266	107,373
Induced Dividend from Warrant Exercises								163,017	$ 1,591,080
Class of Warrant or Right, Exercised During Period, Intrinsic Value								62,660
Class of Warrant or Right, Issued During Period, Fair Value								$ 100,357
Exercise of Warrants for Stock, Shares (in shares)								2,088,667
Warrants Issued to Investors in Private Placements [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)													$ 0.03
Warrants Issued to Investors in Private Placements [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)													$ 0.05
Warrants Issued to Researcher as Compensation [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)								1
Warrants and Rights Outstanding, Term (Year)								10 years
Class of Warrant or Right, Issued During Period (in shares)								600,000
Class of Warrant or Right, Issued During Period, Exercise Price (in dollars per share)								$ 0.05
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price (in dollars per share)								$ 0.048
Convertible Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)						$ 0.10			$ 0.10
Class of Warrant or Right, Issued During Period (in shares)									788,000
Class of Warrant or Right, Extension Period of Securities Called by Warrants or Rights (Year)									3 years
Warrants and Rights Outstanding						$ 13,396			$ 13,396
Employees and Director Warrants [Member] | Employees and Directors [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)				$ 0.04
Warrants and Rights Outstanding, Term (Year)				10 years
Share-based Payment Arrangement, Expense				$ 133,000
Warrants and Rights Outstanding				$ 133,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)				3,500,000
Compensation Warrants Issued to Brokers [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.01
Warrants and Rights Outstanding		$ 367,196										$ 135,861
Class of Warrant or Right, Outstanding (in shares)		9,424,613
Class of Warrant or Right, Expense		$ 231,335
Compensation Warrants Issued to Brokers [Member] | Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 0.25
Compensation Warrants Issued to Brokers [Member] | Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)												$ 1
Replacement Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)											$ 0.10
Warrants and Rights Outstanding, Term (Year)											3 years
Warrants and Rights Outstanding											$ 1,182,920
Class of Warrant or Right, Outstanding (in shares)											42,705,809

Note 9 - Capital Transactions -

Note 9 - Capital Transactions - Warrant Activity (Details) - $ / shares	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Outstanding (in shares)	85,843,036	84,538,161
Warrants issued (in shares)	2,095,333	43,493,809
Warrants issued, exercise price (in dollars per share)	$ 0.10	$ 0.10
Warrants exercised (in shares)	(9,697,146)	(35,798,809)
Warrants expired/cancelled (in shares)	(3,116,550)	(6,390,125)
Outstanding (in shares)	75,124,673	85,843,036
Minimum [Member]
Warrants exercised, exercise price (in dollars per share)		$ 0.030
Warrants expired/cancelled, exercise price (in dollars per share)		0.60
Maximum [Member]
Warrants exercised, exercise price (in dollars per share)		0.035
Warrants expired/cancelled, exercise price (in dollars per share)		$ 0.90

Note 10 - Employee Benefit Pl_3

Note 10 - Employee Benefit Plan (Details Textual) - USD ($)		11 Months Ended	12 Months Ended
	Dec. 15, 2020	Mar. 03, 2022	Mar. 31, 2022	Mar. 31, 2021	Sep. 17, 2021	Oct. 25, 2018	Jun. 30, 2015	Feb. 06, 2008
Class of Warrant or Right, Expense			$ 60,667	$ 211,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 17,333
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)			0	0
Restricted Stock [Member]
Share-based Payment Arrangement, Expense			$ 0	$ 0
Share-Based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Expense	$ 51,050	$ 60,667	60,667	$ 436,349
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total			$ 17,333
GB Sciences, Inc. 2007 Amended Stock Option Plan [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)								4,500,000
The 2014 Equity Compensation Plan [Member] | Share-Based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)							8,500,000
GB Sciences, Inc 2018 Stock Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)						10,000,000
The 2021 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)			20,000,000		20,000,000

Note 10 - Employee Benefit Pl_4

Note 10 - Employee Benefit Plan - Assumptions (Details) - Share-Based Payment Arrangement, Option [Member]	12 Months Ended
	Mar. 31, 2021
Weighted-average volatility	127%
Expected term (in years) (Year)	10 years
Risk-free interest rate	0.93%

Note 10 - Employee Benefit Pl_5

Note 10 - Employee Benefit Plan - Option Activity (Details) - USD ($)	12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2020
Share-Based Payment Arrangement, Employee [Member]
Outstanding, options (in shares)	17,733,334	10,983,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.11	$ 0.28
Outstanding, weighted average remaining contractual life (Year)	5 years 9 months 18 days	6 years 9 months 18 days	6 years 7 days
Outstanding, aggregate intrinsic value	$ 0	$ 172,000	$ 0
Granted, options (in shares)	0	6,750,000
Granted, weighted average exercise price (in dollars per share)		$ 0.05
Exercised, options (in shares)	0	0
Exercised, weighted average exercise price (in dollars per share)
Forfeited, options (in shares)	0	0
Forfeited, weighted average exercise price (in dollars per share)
Outstanding, options (in shares)	17,733,334	17,733,334	10,983,334
Outstanding, weighted average exercise price (in dollars per share)	$ 0.11	$ 0.11	$ 0.28
Fully vested and expected to vest, options (in shares)	17,733,334
Fully vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.11
Exercisable, options (in shares)	15,566,668
Exercisable, weighted average exercise price (in dollars per share)	$ 0.12
Share-Based Payment Arrangement, Nonemployee [Member]
Outstanding, options (in shares)	5,883,000	2,383,000
Outstanding, weighted average exercise price (in dollars per share)	$ 0.14	$ 0.27
Outstanding, weighted average remaining contractual life (Year)	7 years 3 months 21 days	8 years 1 month 9 days	6 years 9 months
Outstanding, aggregate intrinsic value	$ 0	$ 0
Granted, options (in shares)	600,000	3,500,000
Granted, weighted average exercise price (in dollars per share)	$ 0.05	$ 0.05
Exercised, options (in shares)	0	0
Exercised, weighted average exercise price (in dollars per share)
Forfeited, options (in shares)	0	0
Forfeited, weighted average exercise price (in dollars per share)
Outstanding, options (in shares)	6,483,000	5,883,000	2,383,000
Outstanding, weighted average exercise price (in dollars per share)	$ 0.13	$ 0.14	$ 0.27
Fully vested and expected to vest, options (in shares)	6,483,000
Fully vested and expected to vest, weighted average exercise price (in dollars per share)	$ 0.13
Exercisable, options (in shares)	6,483,000
Exercisable, weighted average exercise price (in dollars per share)	$ 0.13

Note 11 - Commitments and Con_2

Note 11 - Commitments and Contingencies (Details Textual) - USD ($)	Dec. 16, 2020	Sep. 17, 2020	Jul. 14, 2020	Apr. 22, 2020
Repayment of Iliad Note [Member] | Judicial Ruling [Member]
Litigation Settlement, Amount Awarded to Other Party			$ 3,264,594
Litigation Settlement, Payment	$ 3,006,015
Payment of Services Provided by Contractor [Member] | Pending Litigation [Member]
Loss Contingency, Damages Sought, Value				$ 73,050
Payment of Services Provided by Contractor [Member] | Settled Litigation [Member]
Payments for Legal Settlements		$ 25,000
Reduction in Cost Basis of Fixed Asset Related to Litigation		$ 48,050

Note 12 - Related Party Trans_2

Note 12 - Related Party Transactions (Details Textual) - USD ($)			12 Months Ended
	Jan. 02, 2021	Nov. 16, 2020	Mar. 31, 2022	Mar. 31, 2021
Repayments of Related Party Debt			$ 0	$ 151,923
Leslie Bocskor [Member]
Due to Related Parties, Total		$ 78,245
Payments for Postemployment Benefits		6,500
Salary and Wage, Excluding Cost of Good and Service Sold, Total				44,192
Leslie Bocskor [Member] | Unpaid Severance Compensation [Member]
Related Party Transaction, Expenses from Transactions with Related Party		20,000
Related Party Transaction, Amounts of Transaction		$ 84,745
Ksenia Griswold [Member] | Unpaid Severance Compensation [Member]
Due to Related Parties, Total	$ 114,159
Related Party Transaction, Amounts of Transaction	57,000
Other Income	$ 57,159
John Davis [Member]
Notes Payable, Related Parties, Current				$ 151,923
Officers and Directors [Member]
Repayments of Related Party Debt			84,913
Due to Related Parties, Total			$ 0

Note 13 - Sale of Membership _3

Note 13 - Sale of Membership Interests in Nevada Subsidiaries (Details Textual)							9 Months Ended		12 Months Ended
	Dec. 31, 2021 USD ($)	Dec. 14, 2021 USD ($)	Aug. 10, 2020 USD ($)	Mar. 24, 2020 USD ($)	Nov. 27, 2019	Oct. 23, 2017	Dec. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)
Notes Reduction										$ 2,612,854	$ 0
Proceeds from Divestiture of Interest in Consolidated Subsidiaries										1,648,772	0
Deconsolidation, Gain (Loss), Amount	$ 5,206,208									5,206,208	$ 0
Promissory Note [Member] | The 0% Note Payable Dated October 23, 2017 [Member]
Debt Instrument, Interest Rate, Stated Percentage			0%			0%
Receivable with Imputed Interest, Effective Yield (Interest Rate)						20.30%
GB Sciences Nopah, LLC [Member]
Sale of Stock, Percentage of Ownership					100%
Noncash or Part Noncash Divestiture, Amount of Consideration Received			$ 312,315
Nevada Subsidiaries [Member]
Sale of Stock, Percentage of Ownership				100%
Teco Subsidiaries [Member]
Sale of Stock, Consideration Received on Transaction				$ 8,000,000
Notes Receivable, Interest Rate				8%
GB Sciences Nopah, LLC [Member]
Notes Reduction			237,668
Extinguishment of Debt, Amount							$ 3,462,854	$ 3,462,854
Sale of Stock, Percentage of Ownership before Transaction	100%
Sale of Stock, Percentage of Ownership after Transaction	0%
Proceeds from Divestiture of Interest in Consolidated Subsidiaries								1,648,772		$ 1,648,772
Proceeds From Divestiture of Business, Advances Received	$ 400,000						400,000	400,000
Financing Receivable, after Allowance for Credit Loss, Total	3,025,000						$ 3,025,000	$ 3,025,000
Receivable with Imputed Interest, Effective Yield (Interest Rate)							8%	8%
Deconsolidation, Gain (Loss), Amount								$ 5,206,208
Note Receivable, Interest Only, Monthly									$ 60,500
Quarterly Interest Only Payments on Note Receivable, Years									1	1
Number of Quarterly Principal and Interest Payments on Note Receivable									7	7
Note Receivable, Quarterly Principal and Interest Installment										$ 201,774
Final Payment, Principal and Interest Payments Due on Note Receivable									$ 2,014,225	2,014,225
Asset Impairment Charges, Total										$ 3,025,000
GB Sciences Nopah, LLC [Member] | Accounts Payable Due to Affiliate of the Purchaser [Member]
Extinguishment of Debt, Amount	$ 74,647	$ 74,647	$ 74,647

Note 13 - Sale of Membership _4

Note 13 - Sale of Membership Interests in Nevada Subsidiaries - Gain on Deconsolidation (Details) - USD ($)		12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Cash payments received, including advancements of $400,000		$ 1,648,772	$ 0
8% Note Receivable due December 31, 2024		3,025,000	0
Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates		2,612,854	0
Extinguishment of accrued management fees due to purchaser		850,000	0
GAIN ON DECONSOLIDATION	$ 5,206,208	$ 5,206,208	$ 0
Nevada Subsidiaries [Member]
Cash payments received, including advancements of $400,000	1,648,772
8% Note Receivable due December 31, 2024	3,025,000
Extinguishment of debt and accrued interest due to purchasers and purchasers' affiliates	2,612,854
Extinguishment of accrued management fees due to purchaser	850,000
Total consideration	8,136,626
Carrying amount of assets	7,130,159
Carrying amount of liabilities	(4,199,741)
Net assets deconsolidated	$ 2,930,418

Note 14 - Concentrations (Detai

Note 14 - Concentrations (Details Textual) - USD ($)	Mar. 31, 2022	Mar. 31, 2021
Cash, Uninsured Amount	$ 0	$ 513,901

Note 15 - Subsequent Events (De

Note 15 - Subsequent Events (Details Textual) - USD ($)	May 09, 2022	Jul. 18, 2021
Warrants Issued to Investors in Private Placements [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)		1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)		$ 0.10
Warrants and Rights Outstanding, Term (Year)		3 years
Subsequent Event [Member]
Sale of Units, Maximum Units Allowed in Private Placement	$ 565,000
Sale of Unit, Price Per Unit (in dollars per share)	$ 0.03
Subsequent Event [Member] | Warrants Issued to Investors in Private Placements [Member]
Number of Warrant Received, Per Unit (in shares)	1
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.10
Warrants and Rights Outstanding, Term (Year)	5 years
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)	4,166,667
Subsequent Event [Member] | Private Placement [Member]
Number of Common Stock Received, Per Unit (in shares)	1
Proceeds from Issuance of Private Placement	$ 125,000
Stock Issued During Period, Shares, New Issues (in shares)	4,166,667